DSGN Earnings

DSGN reported its earnings on 2026-03-09, showcasing a revenue of against an estimate of , resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.38 by 0%. The stock experienced a 3.18% price change on the earnings day and a -0.3% change over the next five days, reflecting market reactions to the results.

Following DSGN's earnings announcement on 2026-03-09, the stock price moved by 3.18% on the day of the release. Over the subsequent five days, it saw a -0.3% change. Historically, DSGN's stock price tends to shift by an average of -3.69% in the 10 days leading up to earnings and -6.81% in the 10 days following, providing insight into potential market.

For , analysts estimate DSGN's annual revenue to reach undefined, while the EPS is projected at -0.36. These estimates reflect recent revisions, with revenue estimates revised upward by 38.64% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between DSGN's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for were revised upward by 38.64%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, DSGN's stock price typically moves by -3.69% in the 10 days before its earnings and -6.81% in the 10 days after. For the upcoming earnings, analysts expect an EPS of -0.36 and revenue of undefined.

The earnings call summary lacks significant financial details, such as revenue, margins, or cash flow, which prevents a strong positive or negative rating. The RESTORE-FA trial is progressing well, yet its success is critical and faces competition from an existing approved drug. Regulatory and clinical trial risks are present. The absence of any discussion on shareholder returns or strategic financial guidance further supports a neutral sentiment, with potential stock movement likely to be within the -2% to 2% range.